Drugs for Carcinoid Syndrome

Find financial assistance programs available for carcinoid syndrome drugs.

Sandostatin LAR Depot (octreotide acetate) for injectable suspension

Drug company: Novartis

Sandostatin LAR is a somatostatin analog used for the longterm treatment of patients with severe diarrhea or flushing episodes associated with metastatic carcinoid tumors.

Novartis Patient Assistance NOW Oncology provides 2 financial assistance programs for patients using Sandostatin LAR Depot:

Novartis Oncology Universal Co-pay Program

Patients with private insurance will pay up to $25 per month in copay and co-insurance. The program pays the remaining balance for Sandostatin LAR Depot until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

For patients without insurance, to be eligible for financial assistance through this program, a patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Sandostatin LAR Depot for free until prescription drug coverage becomes available to them.

Somatuline Depot (lanreotide) Injection

Drug company: Ipsen

Somatuline Depot is a somatostatin analog used for the treatment of adults with carcinoid syndrome tumors, and reduces the frequency of short-acting somatostatin analog rescue therapy.

Ipsen Cares offers 2 financial assistance programs for patients using Somatuline Depot:

Somatuline Depot Virtual Copay Savings Program

Eligible patients with private insurance pay no more than $5 per prescription with this program for 12 months, 13 injections, or for a maximum copay benefit of $20,000 (whichever comes first). Patients with no insurance, or those whose insurance does not cover Somatuline Depot, may pay more than $5 per prescription and their maximum copay benefit amount for prescriptions is $1,666.66, up to an annual maximum of $20,000.

Somatuline Depot Patient Assistance Program

Eligible patients who are experiencing financial hardship, or who have no insurance coverage, and meet specific medical criteria will receive Somatuline Depot for free.

Xermelo (telotristat ethyl) Tablets

Drug company: TerSera Therapeutics

Xermelo is a tryptophan hydroxylase inhibitor used for the treatment of patients with carcinoid syndrome diarrhea, in combination with a somatostatin analog, in adults whose disease is inadequately controlled by somatostatin analog therapy.

TerSera Therapeutics offers 2 financial assistance programs for patients using Xermelo:

Xermelo Co-pay Program

For patients with private insurance, TerSera Therapeutics may provide Xermelo with a $0 copay assistance and up to $10,000 annually.

Xermelo Patient Assistance Program

For patients without commercial insurance, TerSera Support Source may provide Xermelo for free for up to 1 year before renewal is required. Eligible patients should complete the enrollment form and have their physicians complete it as well.

Table. Drugs Prescribed for Carcinoid Syndrome

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Xermelo (telotristat ethyl) Tablets
  • Drug company
  • TerSera Therapeutics
  • Indication
  • Treatment of carcinoid syndrome diarrhea, in combination with a somatostatin analog
  • Patient support services
  • Xermelo Co-pay Program

    TerSera Support Source

Share this:

Last modified: March 17, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest
Other Interests